INTRODUCTION: Quality of life (QOL) is an important treatment endpoint in advanced cancer patients with brain metastases. In clinical trials, statistically significant changes can be reached in a large enough population; however, these changes may not be clinically relevant. OBJECTIVE: The objective of this study was to determine the minimal clinically important difference (MCID) for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire brain module (EORTC QLQ-BN20) in patients with brain metastases. METHODS: Patients undergoing radiotherapy for brain metastases completed the EORTC QLQ-BN20 and QLQ-C30/C15-PAL at baseline and 1-month follow-up. MCIDs were calculated for both improvement and deterioration using anchor- and distribution-based approaches. The anchor of overall QOL (as assessed by question 30 or question 15 on the QLQ-C30 and QLQ-C15-PAL, respectively) was used to determine meaningful change. RESULTS: A total of 99 patients were included. The average age was 61 years, and the most common primary cancer sites were the lung and breast. Statistically significant meaningful differences were seen on two scales. A decrease of 6.1 (95 % confidence interval (CI) 0.8 to 11.4) units and 13.8 (0.2 to 27.4) units was required to represent clinically relevant deterioration of seizures and weakness of legs, respectively. Distribution-based MCID estimates tended to be closer to 0.5 SD on the EORTC QLQ-BN20. CONCLUSION: Understanding MCIDs allows physicians to determine the impact of treatment on patients' QOL and allows for determination of sample sizes for clinical trials. Future studies should be conducted to validate our findings in a larger population of patients with brain metastases.
INTRODUCTION: Quality of life (QOL) is an important treatment endpoint in advanced cancerpatients with brain metastases. In clinical trials, statistically significant changes can be reached in a large enough population; however, these changes may not be clinically relevant. OBJECTIVE: The objective of this study was to determine the minimal clinically important difference (MCID) for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire brain module (EORTC QLQ-BN20) in patients with brain metastases. METHODS:Patients undergoing radiotherapy for brain metastases completed the EORTC QLQ-BN20 and QLQ-C30/C15-PAL at baseline and 1-month follow-up. MCIDs were calculated for both improvement and deterioration using anchor- and distribution-based approaches. The anchor of overall QOL (as assessed by question 30 or question 15 on the QLQ-C30 and QLQ-C15-PAL, respectively) was used to determine meaningful change. RESULTS: A total of 99 patients were included. The average age was 61 years, and the most common primary cancer sites were the lung and breast. Statistically significant meaningful differences were seen on two scales. A decrease of 6.1 (95 % confidence interval (CI) 0.8 to 11.4) units and 13.8 (0.2 to 27.4) units was required to represent clinically relevant deterioration of seizures and weakness of legs, respectively. Distribution-based MCID estimates tended to be closer to 0.5 SD on the EORTC QLQ-BN20. CONCLUSION: Understanding MCIDs allows physicians to determine the impact of treatment on patients' QOL and allows for determination of sample sizes for clinical trials. Future studies should be conducted to validate our findings in a larger population of patients with brain metastases.
Authors: John T Maringwa; Chantal Quinten; Madeleine King; Jolie Ringash; David Osoba; Corneel Coens; Francesca Martinelli; Jurgen Vercauteren; Charles S Cleeland; Henning Flechtner; Carolyn Gotay; Eva Greimel; Martin J Taphoorn; Bryce B Reeve; Joseph Schmucker-Von Koch; Joachim Weis; Egbert F Smit; Jan P van Meerbeeck; Andrew Bottomley Journal: Support Care Cancer Date: 2010-10-01 Impact factor: 3.603
Authors: David Cella; David T Eton; Diane L Fairclough; Philip Bonomi; Anne E Heyes; Cheryl Silberman; Michael K Wolf; David H Johnson Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437
Authors: A Bezjak; J Adam; R Barton; T Panzarella; N Laperriere; C S Wong; W Mason; C Buckley; W Levin; M McLean; J S Y Wu; M Sia; P Kirkbride Journal: Eur J Cancer Date: 2002-03 Impact factor: 9.162
Authors: Minesh P Mehta; Nina A Paleologos; Tom Mikkelsen; Paula D Robinson; Mario Ammirati; David W Andrews; Anthony L Asher; Stuart H Burri; Charles S Cobbs; Laurie E Gaspar; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Michael McDermott; Jeffrey J Olson; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis Journal: J Neurooncol Date: 2009-12-04 Impact factor: 4.130
Authors: Srinivas Raman; Keyue Ding; Edward Chow; Ralph M Meyer; Yvette M van der Linden; Daniel Roos; William F Hartsell; Peter Hoskin; Jackson S Y Wu; Abdenour Nabid; Rick Haas; Ruud Wiggenraad; Scott Babington; William F Demas; Carolyn F Wilson; Rebecca K S Wong; Liting Zhu; Michael Brundage Journal: Qual Life Res Date: 2017-11-29 Impact factor: 4.147
Authors: Janneke van Roij; Heidi Fransen; Lonneke van de Poll-Franse; Myrte Zijlstra; Natasja Raijmakers Journal: Qual Life Res Date: 2018-02-10 Impact factor: 4.147
Authors: Ahmad Ousmen; Célia Touraine; Nina Deliu; Francesco Cottone; Franck Bonnetain; Fabio Efficace; Anne Brédart; Caroline Mollevi; Amélie Anota Journal: Health Qual Life Outcomes Date: 2018-12-11 Impact factor: 3.186
Authors: Ulrica Langegård; Per Fransson; Thomas Bjork-Eriksson; Birgitta Johansson; Emma Ohlsson-Nevo; Katarina Sjövall; Karin Ahlberg Journal: Tech Innov Patient Support Radiat Oncol Date: 2021-02-12